Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic Gastrectomy

The Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic Gastrectomy: Prospective, Double Blind Placebo-controlled Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04493125

Enrollment

104

Registered

2020-07-30

Start date

2020-07-27

Completion date

2021-03-30

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Cancer

Keywords

Gastrectomy, Intestinal motility, Mosapride, Adhesion, Ileus

Brief summary

Mosapride citrate is a 5-hydroxytryptamine 4 receptor agonist, and is widely used as an agent to increase intestinal motility. Mosapride citrate has been demonstrated in in vitro and in vivo studies to increase both gastric and colon motility. In a case-control study of patients undergoing colonectomy, mosapride citrate was found to significantly reduce gas passing and defecation time. Recently, a study reported that mosapride citrate acts on the α7nACh receptor and, consequently, suppresses the inflammatory response of macrophages, thereby suppressing the mechanism that induces paralysis after surgery. To date, this study is intended to analyze whether mosapride citrate significantly affects the improvement of bowel movement after surgery after gastrectomy.

Interventions

DRUGMosapride citrate

Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.

DRUGPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 79 Years

Healthy volunteers

Inclusion criteria

1. Patients diagnosed with gastric cancer pathologically before surgery 2. Patients who underwent surgical resection (R0 resection) 3. Patients with an ASA score of 3 or less

Exclusion criteria

1. Patients over 80 years old 2. When there are multiple or peritoneal metastases 3. Intestinal obstruction before surgery 4. When chemotherapy was performed before surgery 5. When cancer other than stomach cancer is diagnosed 6. If you have a long history of major intra-abdominal surgery or a history of abdominal radiotherapy 7. In case of liver failure or kidney failure 8. When it is judged that uncontrolled diabetes may affect intestinal function

Design outcomes

Primary

Measure	Time frame	Description
The number of radiopaque markers transferred to the large intestine 3 days after surgery	3 Days after surgery	Intestinal motility after gastrectomy

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026